Biotech startups can extend their financial runway by planning cash around scientific milestones rather than calendar months. This involves creating a milestone-based budget, forecasting cash burn under multiple scenarios, managing contract research expenses, securing non-dilutive funding such as government grants and R&D tax credits, and preparing for the next fundraising round before cash reserves become critically low. fractional CFO for biotech companies
In most industries, running low on cash creates a serious business challenge. In biotechnology, it can threaten an entire research program that has taken years to develop. A promising compound, innovative platform technology, or diagnostic product can lose momentum simply because funding runs out a few months before the data needed to secure the next investment round becomes available.
Research timelines can change, experiments may need to be repeated, and regulatory approvals can take longer than expected. Meanwhile, operating expenses continue to accumulate.
This is why many life science founders engage a fractional CFO for biotech companies before they can justify hiring a full-time chief financial officer. The objective is to make every dollar of investor capital last as long as possible while helping the company achieve the scientific milestones that create value.
This guide explores practical cash planning strategies that help biotech startups maintain financial stability and move confidently between funding rounds.
Why Cash Planning Is Different for Biotech Startups
Biotechnology companies face financial challenges that differ significantly from those of traditional businesses. A software company may increase prices, reduce marketing expenses, or generate additional revenue relatively quickly. Early-stage biotech companies often have limited revenue and depend heavily on investor funding.
Their research programs also involve specialized expenses that cannot always be reduced without affecting scientific progress.
Several factors make biotech cash planning particularly challenging:
Uncertain scientific outcomes: Study results can substantially affect company valuation, development priorities, and future fundraising opportunities.
Irregular spending patterns: Contract research, clinical trials, and manufacturing activities often require large payments at specific stages.
Long lead times: Laboratory materials, specialized equipment, and contract research organization services may require months of preparation.
Milestone-dependent financing: Investors frequently expect companies to achieve specific scientific or regulatory objectives before providing additional capital.
Specialized employees: Experienced scientific professionals are expensive to recruit and difficult to replace, making poorly planned staffing reductions risky.
A conventional annual budget rarely addresses these challenges adequately. Biotech companies need financial plans that connect spending decisions directly to the research milestones that support future financing.
Build a Budget Around Scientific Milestones
A milestone-based budget organizes expenses around measurable scientific, clinical, and regulatory achievements rather than focusing exclusively on departments or monthly spending categories.
Examples include completing investigational new drug (IND)-enabling studies, generating proof-of-concept data, completing manufacturing validation, or conducting a first-in-human clinical trial.
The most important question is straightforward: How much capital does the company need to reach its next value-creating milestone?
Steps to Create a Milestone-Based Budget
- Identify the next critical milestones.
Determine which scientific results, regulatory approvals, or clinical outcomes will support the next funding round. Define the expected deliverables and target dates as clearly as possible.
- Map the activities required to achieve each milestone.
Include laboratory experiments, contract research, manufacturing, regulatory submissions, materials, employee costs, and external consulting services.
- Estimate costs and timelines realistically.
Work with scientific leadership, project managers, vendors, and financial professionals to develop estimates based on current contracts and operational requirements.
- Include a contingency reserve.
Experiments can fail, manufacturing batches may require repetition, and regulatory processes can experience delays. A contingency reserve helps protect the company from unexpected expenses.
- Separate essential expenses from deferrable spending.
Identify which activities must continue and which can be postponed without jeopardizing critical research objectives.
This budgeting method improves board discussions by shifting attention from individual expense categories to the company's ability to achieve important scientific outcomes.
Forecast Cash Burn Under Multiple Scenarios
A single financial forecast can create a misleading sense of security. Biotech startups should model multiple scenarios to understand how changes in research timelines, expenses, and funding availability affect their financial runway.
Scenario
Key Assumptions
Primary Purpose
Base case
Milestones occur according to the current plan
Supports routine financial management
Delay case
Critical studies take three to six months longer
Tests the impact of research delays
Lean case
Nonessential programs pause and hiring slows
Identifies opportunities to preserve cash
Upside case
A grant, partnership, or favorable result arrives earlier
Evaluates opportunities to accelerate development
Every scenario should include projected monthly cash balances, expected cash burn, upcoming payment obligations, and the estimated date when cash reserves approach a minimum safety threshold.
Leadership should review these forecasts monthly and update them using actual financial results.
Working with experienced cash flow management consulting professionals can help startups establish rolling forecasts that reflect changing research timelines, vendor commitments, and funding expectations.
Rather than relying on assumptions established during the previous fundraising round, founders can make decisions using current financial information.
Control the Largest Cost Drivers
A relatively small number of expense categories often account for most of a biotech startup's monthly cash burn. Improving financial oversight in these areas can meaningfully extend runway.
Contract Research and Manufacturing
Contract research organizations (CROs) and contract manufacturers can represent substantial expenses.
Review vendor agreements for payment schedules, cancellation provisions, change-order fees, and project deliverables. Where possible, structure payments around completed work rather than paying substantially ahead of progress.
Regularly compare the work performed with the amounts invoiced or paid.
Employee and Contractor Expenses
Scientific salaries, benefits, and recruitment costs can consume significant capital.
Evaluate whether certain specialized tasks can temporarily be handled by consultants or contract scientists. However, avoid reducing essential scientific capacity simply to achieve short-term savings.
Laboratory Space and Equipment
Shared laboratory facilities, incubators, and equipment leasing can reduce upfront commitments.
Purchasing expensive equipment before it becomes essential may tie up cash that would be better allocated to experiments, manufacturing, or regulatory activities.
Research Materials and Supplies
Specialized reagents, cell lines, and laboratory materials may involve long lead times and high prices.
Coordinating purchasing schedules, monitoring inventory, and avoiding duplicate orders can help reduce waste, rush charges, and unnecessary spending.
Research Accruals and Financial Reporting
Research expenses frequently occur before vendors issue their invoices.
Accurate monthly accruals ensure that financial statements reflect expenses incurred during the reporting period. Without them, a startup may underestimate its actual spending and mistakenly believe it has more runway than it does.
Reliable accounting is therefore an essential component of biotech cash planning.
Secure Non-Dilutive Funding Opportunities
Non-dilutive funding provides capital without requiring the company to issue additional equity. These sources can help preserve ownership for founders and existing investors while supporting research and development.
Government Research Grants
Programs such as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR), along with grants from the National Institutes of Health and other government agencies, may support eligible research projects.
However, grants usually involve application requirements, spending restrictions, documentation, and compliance obligations. Strong financial controls are necessary to manage these responsibilities.
R&D Tax Credits
Research involving new compounds, therapies, diagnostics, and platform technologies may qualify for research tax incentives, depending on the applicable rules and the company's activities.
Specialized R&D tax credit consulting can help identify potentially qualifying wages, supplies, and contract research expenses.
Certain eligible small businesses that are not yet profitable may be able to apply a portion of their federal research credit against payroll taxes. This can create a near-term cash benefit without requiring taxable income.
Eligibility limits and documentation requirements apply. Research funded by grants or other parties may also receive different treatment when calculating eligible expenses, so grant funding and tax credit planning should be coordinated.
Strategic Partnerships
Licensing agreements, research collaborations, and co-development arrangements can provide upfront payments, milestone-based compensation, and access to additional resources.
These arrangements may also validate the commercial potential of a company's technology.
Venture Debt
Venture debt can extend the financial runway of startups with strong investor support. However, it introduces repayment obligations, interest costs, and potentially restrictive financial or operational covenants.
Founders should evaluate these commitments under several cash flow scenarios before accepting financing.
Protect Existing Cash Reserves
Extending runway does not always mean cutting expenses. It also requires managing existing capital carefully.
Biotech leadership teams should consider the following practices:
Establish a minimum cash threshold that triggers predefined financial actions.
Review banking relationships and deposit protection arrangements to manage concentration risk.
Keep operating reserves in liquid, appropriately low-risk instruments consistent with the company's investment policy.
Introduce spending approval limits for significant purchases and long-term commitments.
Review cash balances, outstanding liabilities, and forecast changes with the board regularly.
Compare actual spending with budgeted expenses and investigate unexpected differences promptly.
These measures improve financial visibility and give leadership more time to respond when research costs or timelines change.
Start Fundraising Before Cash Becomes Critical
One of the most costly mistakes a biotech startup can make is waiting until its cash reserves are nearly exhausted before beginning fundraising.
Capital raises can take six months or longer, depending on market conditions, investor interest, company performance, and the complexity of the transaction.
Investors may also become more cautious when a company has insufficient funding to reach its next scientific milestone without additional capital.
Preparation should begin while the company still has enough resources to execute its research plan and withstand reasonable delays.
A fundraising preparation checklist should include:
Updating the financial model and cash runway forecast.
Reviewing accounting records and outstanding research accruals.
Organizing the investor data room and capitalization table.
Preparing a clear use-of-funds plan.
Connecting funding requirements to specific scientific milestones.
Developing base-case and downside-case financial projections.
Identifying prospective investors, strategic partners, and alternative funding sources.
A well-prepared company can communicate its financial requirements more clearly and approach investors from a stronger position.
How K-38 Consulting Supports Biotech Financial Planning
K-38 Consulting, a finance firm based in Raleigh, North Carolina, and founded by Dallas Alford IV, CPA, provides CFO support to startups and midsize businesses across the United States.
Its service model combines controller-level accounting support with CFO-level financial planning. The controller focuses on reliable bookkeeping, research accruals, and monthly financial reporting, while the CFO concentrates on cash runway, milestone budgeting, scenario forecasting, funding strategy, and fundraising preparation.
For biotech founders, this arrangement can connect financial management directly to research objectives without requiring the company to hire a full-time internal finance department.
K-38 Consulting also provides R&D tax credit services, helping eligible businesses evaluate research-related tax incentives as part of their broader funding strategy.
The firm works with established accounting platforms such as QuickBooks and NetSuite and uses web-based forecasting tools to help leadership monitor cash balances, spending patterns, and future funding requirements.
The firm reports that many businesses spend 10 to 15 hours monthly on manual accounting activities, making automation an important consideration when improving financial operations.
According to the firm's client materials, Dover Therapeutics, a biotech startup, has credited K-38 Consulting with helping improve financial operations, cash flow, business processes, and financial forecasting.
K-38 Consulting serves businesses in several U.S. markets, including Raleigh, Charlotte, Atlanta, Tampa, Miami, Austin, New York City, Chicago, San Francisco, San Jose, and Los Angeles.
Biotech founders considering outside financial support can explore whether a fractional CFO arrangement would help them improve runway visibility, prepare for upcoming financing, and manage research spending more effectively.
Biotech Runway Stress Test: Eight Questions for Leadership
Use these questions during financial reviews and board meetings to identify potential weaknesses in the company's cash planning.
Do we know how much capital is required to reach the next major scientific milestone?
Does our forecast account for research delays and unexpected expenses?
Are research accruals recorded accurately every month?
Are CRO and manufacturing payments linked to deliverables wherever practical?
Have we evaluated eligibility for applicable R&D tax credits and payroll tax offsets?
Are we pursuing grants, partnerships, or other funding sources that fit our research programs?
Do we have a defined minimum cash threshold and a realistic contingency plan?
When must fundraising begin to close before our cash reserves become critically low?
If the leadership team cannot confidently answer these questions, improving financial visibility should become an immediate priority.
Frequently Asked Questions About Biotech Cash Planning
- How much financial runway should a biotech startup maintain after a funding round?
The appropriate runway depends on the company's research program, upcoming milestones, development costs, and fundraising environment. Many startups plan to have enough capital to reach the next significant milestone while retaining a buffer for delays and unexpected expenses.
- How can a biotech startup extend its cash runway?
Startups can extend runway by prioritizing essential research, negotiating vendor payment schedules, improving inventory management, reviewing staffing requirements, pursuing non-dilutive funding, and updating cash forecasts regularly.
The goal is to reduce avoidable spending without compromising the scientific milestones necessary for future financing.
- Can a pre-revenue biotech company qualify for R&D tax credits?
Potentially. Certain eligible small businesses may elect to apply a portion of the federal research credit against qualifying payroll taxes even when they have no income tax liability. The company must satisfy applicable eligibility, election, and documentation requirements.
- Why are research accruals important for biotech startups?
Research accruals record expenses when the underlying work occurs, even if the invoice has not yet arrived. Accurate accruals help companies understand their actual spending, prepare reliable financial statements, and avoid overstating available runway.
- When should a biotech startup hire a fractional CFO?
A startup may benefit from fractional CFO support before a major funding round, during expensive preclinical or clinical development, when applying for significant grants, or when financial forecasts become difficult to manage internally.
The timing depends on operational complexity and the company's available financial resources.
- What is a milestone-based budget?
A milestone-based budget organizes expenses around defined scientific, clinical, and regulatory objectives. It helps leadership determine how much money is required to achieve a specific result and whether current capital is sufficient to reach it.
- Are government grants better than venture capital?
Neither funding source is universally better. Grants can provide non-dilutive support for eligible research, while venture capital can provide larger amounts of flexible financing in exchange for equity.
Companies should evaluate funding options according to eligibility, timing, reporting requirements, dilution, and strategic objectives.
- Should biotech startups consider venture debt?
Venture debt may be useful for companies with strong investor backing and a credible repayment strategy. However, interest, repayment schedules, and contractual covenants can increase financial pressure. Founders should model the consequences of delayed milestones or fundraising before taking on debt.
- How often should a biotech company update its cash forecast?
Monthly updates are a practical minimum for many early-stage companies. Startups experiencing rapid spending changes, major clinical activities, or fundraising uncertainty may need more frequent reviews.
Forecasts should incorporate actual expenses, updated vendor commitments, revised research timelines, and changes in funding expectations.
- How can a fractional CFO help prepare a biotech company for fundraising?
A fractional CFO can help develop financial projections, calculate runway, organize financial records, model funding requirements, evaluate alternative scenarios, and connect capital requirements to scientific milestones. These activities help founders explain how additional investment will support the company's development plan.
Conclusion: Buying Time for Scientific Progress
In biotechnology, time is one of the most valuable resources a company has, and cash is what makes that time possible.
Founders who budget around scientific milestones, forecast multiple outcomes, manage major expenses, maintain accurate accounting records, and pursue non-dilutive funding can improve their chances of reaching the results that matter.
Financial planning cannot eliminate scientific uncertainty, but it can help companies prepare for setbacks without losing sight of their research objectives.
With the right financial processes and experienced CFO support, biotech startups can make better use of available capital, prepare for fundraising earlier, and give promising scientific programs a stronger opportunity to progress from research to meaningful commercial outcomes.